Read Researcher Dr. Matthew Triolo’s Early-Career Blog
Read the latest early-career blog post, from NMD4C member and researcher Dr. Matthew Triolo.
“I always try to get one message across – although this was not my initial dream, it stemmed from a series of lived experiences, as you will see below. Ultimately, I learned that life and career aspirations are malleable, they change based on the experiences we have and the blending of interests from different realms of our life.“
Dr. Matthew Triolo is a Postdoctoral Fellow working within Dr. Mireille Khacho’s lab in the Faculty of Medicine at the University of Ottawa. Matthew first completed his BSc in Kinesiology and Health Science with a Minor in Biology at York University. After completing his MSc investigating whether electrical pulse stimulation can enhance muscle cell activity under the guidance of Dr. Michael Connor, he subsequently worked towards his PhD as a member of the Muscle Health Research Centre at York University. While under the supervision of Dr. David Hood, his work focused on skeletal muscle autophagy, mitophagy and lysosome biogenesis in the context of aging, disuse, and exercise. As a new Postdoctoral Fellow, Dr. Triolo is investigating mechanisms by which mitochondria regulate muscle stem cell homeostasis and function. He enjoys playing a variety of sports including hockey, golf and baseball, and spending time with his family, friends, and cat, Luna.
Read next...
New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada
We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Kerri Lynn Schellenberg, Homira Osman, Maria Masnata, Rhiannon Hicks, Corinne Kagan, Ana Stosic, Stacey Lintern, Erin Beattie, Drs. Hanns Lochmüller, Craig Campbell, and Jean K Mah. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.
Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy
NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.
Advancing AFC in Neuromuscular Medicine: Program Launch & September Workshop
The Royal College has approved National Training Standards for the AFC in Neuromuscular Medicine, creating a formal pathway to recognize enhanced competence with the DRCPSC credential. This designation establishes a national training standard, supports portable certification, and strengthens clinical capacity across Canada. PGME offices can now apply to offer accredited AFC programs, with a goal of five programs submitting applications by the end of 2026.